Back to today’s briefing

Story perspectives

Viking Therapeutics Stock Plummets Amid Rival Treatment Alliance

1/5/2025

50 6

Summary

Story summary

Viking Therapeutics saw its stock plummet by 24% in December 2024, shaken by Merck's alliance with Hansoh Pharma to advance HS-10535, a rival to its oral obesity treatment, VK2735. Yet, Viking holds onto hope, championing VK2735's ease of use compared to injections, as it aims to carve out a niche in the booming obesity market.

1 of 1

Story summary

Viking Therapeutics saw its stock plummet by 24% in December 2024, shaken by Merck's alliance with Hansoh Pharma to advance HS-10535, a rival to its oral obesity treatment, VK2735. Yet, Viking holds onto hope, championing VK2735's ease of use compared to injections, as it aims to carve out a niche in the booming obesity market.